5-O-Methylvisammioside

Synonyms: 4'-O-β-D-Glucosyl-5-O-methylvisamminol
5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) 是一种具有口服活性和多种生物活性的天然色原酮苷,它通过激活 Nrf2/HO-1 信号轴抑制铁死亡 (ferroptosis),通过抑制 ROS/NF-κB/NLRP3 通路改善肠道屏障损伤,通过降低 ALT/AST、减少炎性浸润、抑制 IκB-α 磷酸化和 NF-κB 核转位发挥急性肝损伤保护作用,通过阻断 HMGB1/RAGE/MEK/ERK 信号轴发挥抗肿瘤和血管生成作用,并通过抑制 Src 激酶和 NF-κB 通路改善抑郁样行为。
产品编号: MS-X33772 纯度: 99.90% CAS No.: 84272-85-5 分子式: C22H28O10 分子量: 452.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) 是一种具有口服活性和多种生物活性的天然色原酮苷,它通过激活 Nrf2/HO-1 信号轴抑制铁死亡 (ferroptosis),通过抑制 ROS/NF-κB/NLRP3 通路改善肠道屏障损伤,通过降低 ALT/AST、减少炎性浸润、抑制 IκB-α 磷酸化和 NF-κB 核转位发挥急性肝损伤保护作用,通过阻断 HMGB1/RAGE/MEK/ERK 信号轴发挥抗肿瘤和血管生成作用,并通过抑制 Src 激酶和 NF-κB 通路改善抑郁样行为。

生物实验数据

生物活性 5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is a naturally occurring chromone glycoside with oral activity and multiple bioactivities that inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis, ameliorates intestinal barrier injury by inhibiting the ROS/NF-κB/NLRP3 pathway, exerts protective effects against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation, exerts antitumor and anti-angiogenic effects by blocking the HMGB1/RAGE/MEK/ERK signaling axis, and improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
体外研究
(In Vitro)

5-O-Methylvisammioside 可有效阻断脂多糖诱导 BV-2 小胶质细胞产生的炎症因子。
5-O-Methylvisammioside (50-500 μg/mL; 24 h) 在浓度高达 500 μg/mL 时对人脐静脉内皮细胞无毒性,并呈剂量依赖性抑制 HMGB1 诱导的人脐静脉内皮细胞增殖。
5-O-Methylvisammioside (100-500 μg/mL; 24 h) 在伤口愈合实验中呈剂量依赖性抑制 HMGB1 诱导的人脐静脉内皮细胞迁移。
5-O-Methylvisammioside (100-500 μg/mL; 24 h) 可在 Transwell 实验中剂量依赖性地抑制 HMGB1 诱导的人脐静脉内皮细胞迁移。
5-O-Methylvisammioside (100-500 μg/mL; 16 h) 可剂量依赖性地抑制 HMGB1 诱导的人脐静脉内皮细胞管形成。
5-O-Methylvisammioside (100-500 μg/mL) 呈剂量依赖性地抑制人脐静脉内皮细胞中由 HMGB1 诱导的 RAGE、磷酸化 MEK 及磷酸化 ERK 的上调表达。
5-O-Methylvisammioside (250 μg/mL) 可抑制 HMGB1 诱导的人脐静脉内皮细胞中 RAGE 的上调。
5-O-Methylvisammioside (100-500 μg/mL) 可剂量依赖性地抑制人脐静脉内皮细胞中由 HMGB1 诱导的 VEGF 生成。
5-O-Methylvisammioside (40 μM; 48 h) 可显著降低经 Erastin (MS-C46386) 处理的 Caco-2 细胞的氧化应激水平、纠正铁代谢紊乱、恢复铁死亡相关蛋白表达量并降低炎性细胞因子水平,且这些保护作用严格依赖 Nrf2/HO-1 通路,因为 Nrf2 敲低可显著削弱上述效应。
5-O-Methylvisammioside (10 μM; 45 min) 可强效抑制过表达 CNT2 的 HEK293 细胞中 CNT2 介导的腺苷摄取,其 IC50 为 11.22 μM,在 10 μM 浓度下的活性强于其他受试化合物。
5-O-Methylvisammioside (10 μM; 24 h) 可抑制经 720 μM 尿酸 (UA) (MS-G49441) 刺激 24 h 后的人肠上皮细胞中 ROS 的生成,这一点可通过 DCFH-DA 荧光强度降低以及 SOD/NOX4 mRNA 表达的调控得到证实。
5-O-Methylvisammioside (10 μM; 24 h) 可抑制 ROS/NF-κB/NLRP3 通路的激活,并恢复经 720 μM UA 刺激 24 h 的人肠上皮细胞中的紧密连接蛋白表达。

Cell Migration Assay

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 100, 250, 500 μg/mL
Incubation Time: 24 h
Result: Dose-dependently reduced HMGB1-enhanced wound closure at 100, 250, 500 μg/mL, with significant inhibition observed at all tested concentrations.\n
Significantly reduced the number of HMGB1-increased migrated cells at 100, 250, 500 μg/mL, with dose-dependent inhibition observed.

Western Blot Analysis

Cell Line: UA-stimulated human intestinal epithelial cells (HIEC)
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly reduced phosphorylation of NF-κB p65, and decreased protein expression of NLRP3, ASC, and caspase-1 in UA-stimulated HIEC.
Increased protein expression of tight junction proteins ZO-1 and Occludin in UA-stimulated HIEC.
体内研究
(In Vivo)

5-O-methylvisammioside (5-10 mg/kg;腹腔注射;每日 1 次,连续 7 天) 可通过抑制 TNF、MAPK、NF-κB 和花生四烯酸通路,降低血清肝酶及炎症细胞因子水平,改善肝脏组织病理学特征,缓解 Acetaminophen (MS-H20928) 诱导的雄性 ICR 小鼠急性肝损伤。
5-O-Methylvisammioside (12.5-50 mg/kg;每日一次;连续 14 天) 可剂量依赖性抑制 C57BL/6 小鼠原位肝细胞癌的生长,在 50 mg/kg 剂量下的最大肿瘤抑制率达 62.64%,其作用机制为抑制肿瘤血管生成并下调 HMGB1/RAGE/MEK/ERK 信号通路。
5-O-Methylvisammioside (3.5-7 mg/kg/天;腹腔注射;每日一次,连续 14 天) 可呈剂量依赖性缓解 DSS (MS-A45736) 诱导的雄性 Sprague-Dawley 大鼠溃疡性结肠炎。
5-O-Methylvisammioside (5-20 mg/kg;灌胃;单次给药) 可使单次给药的高尿酸血症 (HUA) 小鼠的血清尿酸峰值降低最多 39.1%(10 mg/kg 剂量),并加快尿酸水平恢复至基线。
5-O-Methylvisammioside (5-20 mg/kg;灌胃,每日一次,连续 4 周) 可降低慢性高尿酸血症小鼠的血清尿酸和腺苷水平,改善肝肾功能,缓解肠道炎症与氧化应激,恢复肠道屏障功能,使肠道 CNT2 表达恢复正常。

Animal Model: ICR (male, adult, 20-22 g, acetaminophen-induced acute liver injury)
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.p.; daily; 7 days
Result: Significantly reduced serum alanine aminotransferase and aspartate aminotransferase levels compared to the acetaminophen-only group.
Significantly reduced liver inflammatory cell infiltration and hepatocyte vacuolation compared to the acetaminophen-only group.
Significantly decreased serum TNF-α and IL-1β levels compared to the acetaminophen-only group.
Significantly suppressed hepatic mRNA expression of TNF-α, IL-1β, Ptges, p38, and RelB compared to the acetaminophen-only group.
Significantly inhibited IκB-α phosphorylation and NF-κB nuclear translocation compared to the acetaminophen-only group.
Significantly suppressed phosphorylation of JNK and p38 in the MAPK pathway compared to the acetaminophen-only group, with no significant effect on Erk1/2 phosphorylation.
Regulated 4675 differentially expressed hepatic genes compared to the acetaminophen-only group, with enrichment in TNF, MAPK, NF-κB, and arachidonic acid pathways at 10 mg/kg dose.
Regulated 249 hepatic metabolites compared to the acetaminophen-only group, including significant reduction in pro-inflammatory prostaglandins (D2, B2, A2) linked to the arachidonic acid pathway at 10 mg/kg dose.
Animal Model: C57BL/6 (male, 8 weeks old, 20g)
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: daily; 14 days
Result: Reduced tumor weight with tumor inhibition rates of 42.24%, 55.48%, and 62.64% for the 12.5 mg/kg, 25 mg/kg, and 50 mg/kg doses, respectively.
Decreased CD31 H-scores in tumor tissues across all three doses.
Exhibited dose-dependent reductions in HMGB1, RAGE, p-MEK, and p-ERK protein levels compared to the model group.
Reduced tumor tissue HMGB1 levels and VEGF levels across all three doses.
Caused no significant changes in body weight during the 14-day period.
Animal Model: Sprague-Dawley (male, 6 weeks old, 200 g, specific pathogen-free, ulcerative colitis induced by 3% dextran sulfate sodium)
Dosage: 3.5 mg/kg/day; 7 mg/kg/day
Administration: i.p.; daily; 14 days
Result: Reduced disease activity index scores compared to the DSS model group, with the high dose showing greater efficacy.
Significantly increased colon length, reduced colon damage index scores, lowered spleen index, and increased thymus index.
Partially ameliorated mucosal ulceration, crypt atrophy, and inflammatory infiltration at low dose; showed improved gland/crypt organization and reduced inflammation, with near-normal mucosa similar to mesalazine at high dose.
Reduced colon tissue levels of IL-6, IL-8, and TNF-α.
Restored goblet cell numbers, upregulated protein and mRNA levels of tight junction proteins occludin and ZO-1.
Reduced oxidative stress markers MDA, 4-HNE, and MPO activity, and increased GSH content.
Reduced total iron content, upregulated FTH1 expression, and downregulated Tfrc and Slc11a2 levels to restore iron homeostasis.
Improved mitochondrial morphology (reduced swelling, increased cristae organization) compared to the DSS group, with high-dose rats showing discernible mitochondrial double membranes.
Upregulated protein and mRNA levels of ferroptosis markers GPX4 and SLC7A11, and downregulated ACSL4.
Dose-dependently upregulated protein and mRNA levels of Nrf2 and HO-1, with high-dose levels exceeding normal control levels.
Animal Model: C57BL/6J (6-week-old, SPF-grade, male, hyperuricemia induced by daily intraperitoneal injection of potassium oxonate plus intragastric gavage of yeast paste for single-dose study)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.g.; single dose
Result: Reduced peak serum uric acid levels to 194.44 μM (5 mg/kg), 174.76 μM (10 mg/kg), 176.93 μM (20 mg/kg).
Lowered peak serum uric acid levels by up to 39.1% (10 mg/kg dose).
Accelerated serum uric acid return to pre-dose levels by 4 h post-treatment.
Animal Model: C57BL/6J (6-week-old, SPF-grade, male, hyperuricemia induced by daily intraperitoneal injection of potassium oxonate plus intragastric gavage of yeast paste for 4 weeks)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.g.; daily; 4 weeks
Result: Significantly reduced serum uric acid levels in all treated groups, with the 10 mg/kg dose showing the greatest reduction.
Significantly decreased serum and urine adenosine levels; 5 and 10 mg/kg doses showed better inhibitory effects on adenosine absorption than positive control drugs.
Significantly reduced elevated CNT2 protein expression in the duodenum, jejunum, and ileum induced by HUA.
Ameliorated liver pathology (bile duct hyperplasia, inflammatory cell infiltration, steatosis) and kidney pathology (renal tubular epithelial cell edema, tubular/corpuscle dilation, inflammatory cell infiltration), and reduced serum ALT, AST, and Cr levels compared to the model group.
Significantly decreased serum and intestinal levels of inflammatory factors (IL-1β, IL-6, TNF-α) and oxidative stress marker MDA, while increased serum SOD levels compared to the model group.
Reduced intestinal permeability (measured via FITC-dextran), and restored intestinal tight junction protein expression (ZO-1, Occludin) in the duodenum, jejunum, and ileum compared to the model group.
Improved intestinal histopathology (epithelial detachment, shortened/sparse villi, inflammatory cell infiltration) and preserved villi structure.
性状 固体
颜色 White to off-white

化学信息

分子量 452.45
分子式 C22H28O10
CAS No. 84272-85-5
别名 4'-O-β-D-Glucosyl-5-O-methylvisamminol

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (22.1 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.42 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (110.51 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : ≥ 25 mg/mL (55.25 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM2.2102 mL11.0509 mL22.1019 mL55.2547 mL
5 mM0.4420 mL2.2102 mL4.4204 mL11.0509 mL
10 mM0.2210 mL1.1051 mL2.2102 mL5.5255 mL
15 mM0.1473 mL0.7367 mL1.4735 mL3.6836 mL
20 mM0.1105 mL0.5525 mL1.1051 mL2.7627 mL
25 mM0.0884 mL0.4420 mL0.8841 mL2.2102 mL
30 mM0.0737 mL0.3684 mL0.7367 mL1.8418 mL
40 mM0.0553 mL0.2763 mL0.5525 mL1.3814 mL
50 mM0.0442 mL0.2210 mL0.4420 mL1.1051 mL
DMSO60 mM0.0368 mL0.1842 mL0.3684 mL0.9209 mL
80 mM0.0276 mL0.1381 mL0.2763 mL0.6907 mL
100 mM0.0221 mL0.1105 mL0.2210 mL0.5525 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

5-O-甲基维斯阿米醇苷 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础